Summary
Eli Lilly and Company's 2009 10-K filing highlights a year of revenue growth driven by key products like Alimta, Cymbalta, Humalog, and Zyprexa, along with the inclusion of Erbitux following the ImClone acquisition. The company also faced significant legal and regulatory challenges, notably related to Zyprexa's marketing practices and ongoing patent litigation for several major products, which resulted in substantial charges and ongoing legal defense costs. Looking ahead, Lilly emphasized its commitment to research and development, with over 60 drug candidates in human testing across various therapeutic areas. However, the company also acknowledged the critical challenge posed by upcoming patent expirations for several of its blockbuster drugs within the next few years, which will likely impact future revenues. Management is focused on cost-reduction initiatives and strategic business development to mitigate these patent cliff impacts and maintain long-term growth.
Financial Highlights
53 data points| Revenue | $21.84B |
| Cost of Revenue | $4.25B |
| Gross Profit | $17.59B |
| R&D Expenses | $4.33B |
| SG&A Expenses | $6.89B |
| Interest Expense | $261.30M |
| Net Income | $4.33B |
| EPS (Basic) | $3.94 |
| EPS (Diluted) | $3.94 |
| Shares Outstanding (Basic) | 1.10B |
| Shares Outstanding (Diluted) | 1.10B |
Key Highlights
- 1Total revenue grew by 7% to $21.84 billion in 2009, primarily driven by Alimta, Cymbalta, Humalog, and Zyprexa, along with the acquisition of ImClone Systems.
- 2The company faced significant legal settlements and charges related to past marketing and promotional practices for Zyprexa, totaling $1.48 billion in 2008 and additional charges in 2009.
- 3Eli Lilly is heavily invested in R&D, with over 60 drug candidates in human testing across key therapeutic areas like CNS, endocrinology, oncology, and cardiovascular diseases.
- 4Several major products are nearing patent expiration, with Zyprexa, Cymbalta, Humalog, and Alimta among those set to lose significant patent protection in the coming years, posing a future revenue risk.
- 5The company is implementing cost-reduction measures, aiming to reduce its expected cost structure by $1 billion by the end of 2011.
- 6Cash flow from operations was robust at $4.34 billion in 2009, supporting debt repayment and dividend payments.
- 7Product liability claims, particularly for Zyprexa, continue to be a significant area of litigation and potential financial exposure for the company.